Because cell surface receptors can be targeted with monoclonal antibodies and fusion toxins, we tested whether the expression of the IL-13 receptors in tumors derived from Tgfbr1/Pten 2cKO mice can be targeted as part of a strategy to treat HNSCC. This evidence concerns the gene TGFBR1 and head and neck squamous cell carcinoma.